ArticleTranslational vision science & technology2025
Long-Term Corneal Reshaping Using Riboflavin-UVA Crosslinking Combined With Decorin in Rabbits.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To establish a preclinical proof of concept for a novel, non-ablative method for long-term corneal reshaping and to investigate its biomechanical and safety profiles. Methods: A rabbit model of non-ablative corneal reshaping was established using a custom molding device. The optimal protocol involved stromal reshaping stabilized by riboflavin-ultraviolet A (UVA) collagen cross-linking (CXL; 7.2 J/cm2), with topical decorin applied as a biological modulator to maintain corneal clarity. Corneal topography was monitored for 12 months. Safety was assessed via in vivo clinical examinations, histology, and electron microscopy. Biomechanical properties were evaluated ex vivo via uniaxial tensile testing of rabbit corneas and human corneal lenticules. Results: In vivo, extensive reshaping with fixation induced significant corneal flattening (6.55 ± 1.44 D at 1 month, stabilizing to 6.19 ± 1.12 D at 12 months; P < 0.05 vs. controls). Mild reshaping yielded 3.13 ± 1.07 D flattening (1 month), but reshaping alone showed no significant effect (P > 0.05). One-month safety evaluations were favorable, demonstrating normal corneal architecture and no cytotoxicity. Ex vivo biomechanics were significantly enhanced by the combined CXL-decorin treatment compared to CXL alone. Conclusions: Combining mechanical molding with a CXL-decorin fixation protocol can achieve durable, non-ablative corneal reshaping, with the observed 12-month stability underpinned by enhanced biomechanical stiffness. This approach is a promising strategy for refractive correction and may have future applications in corneal ectatic diseases. Translational Relevance: This preclinical study validates the long-term safety and efficacy of a non-ablative, stromal-preserving, corneal-reshaping protocol, supporting its potential clinical translation for myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.